La Jolla Pharmaceutical Company CEO Buys $76,240 in Stock (LJPC)

Share on StockTwits

La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George Tidmarsh purchased 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $9.53 per share, for a total transaction of $76,240.00. Following the completion of the purchase, the chief executive officer now directly owns 1,391,086 shares in the company, valued at approximately $13,257,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

LJPC has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of La Jolla Pharmaceutical Company from $32.00 to $33.00 in a research note on Monday, April 7th. Separately, analysts at Noble Financial raised their price target on shares of La Jolla Pharmaceutical Company from $16.00 to $34.00 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Finally, analysts at Chardan Capital raised their price target on shares of La Jolla Pharmaceutical Company to $54.00 in a research note on Tuesday, March 11th. They now have a “positive” rating on the stock.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) opened at 9.09 on Wednesday. La Jolla Pharmaceutical Company has a 52-week low of $0.16 and a 52-week high of $19.50. The stock has a 50-day moving average of $11.00 and a 200-day moving average of $8.86. The company’s market cap is $66.0 million.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last announced its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.24) by $0.17. On average, analysts predict that La Jolla Pharmaceutical Company will post $-2.82 earnings per share for the current fiscal year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer.

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Weekly Research Analysts’ Ratings Changes for athenahealth
Weekly Research Analysts’ Ratings Changes for athenahealth
Chicago Bridge & Iron Company  Set to Announce Quarterly Earnings on Thursday
Chicago Bridge & Iron Company Set to Announce Quarterly Earnings on Thursday
Jarden Corp  Set to Announce Quarterly Earnings on Thursday
Jarden Corp Set to Announce Quarterly Earnings on Thursday
Omnicom Group Shares Gap Up  Following Better-Than-Expected Earnings
Omnicom Group Shares Gap Up Following Better-Than-Expected Earnings
Short Interest in Deere & Company Increases By 11.0%
Short Interest in Deere & Company Increases By 11.0%
Recent Investment Analysts’ Ratings Updates for Costco Wholesale
Recent Investment Analysts’ Ratings Updates for Costco Wholesale


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.